Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for Non-Small-Cell Lung Cancer
Sites in Edmonds +16 more locations
Sponsor: ArriVent BioPharma, Inc.
Sex: All·Age: 18+
Code: NCT07185997·Phase 3·Recruiting·Listed Sep 2025